Retrospective Descriptive Analysis of the Combined First Trimester of Pregnancy Screening in the Period Included from February 2016 to March 2017, Maternal Fetal Medicine Unit, San Juan de Dios Hospital
A
retrospective descriptive study is conducted at the San Juan de Dios Hospital,
San José, Costa Rica, during the period from February 2016 to March 2017, with
a total of 37 patients from which a combined screening during the first
trimester of pregnancy was conducted, evaluating maternal age, biochemical and
sonographic methods that together can predict the risk of fetal chromosomal
alterations during pregnancy. The purpose of using combined screening as a
noninvasive method is to identify high risk gestations and to minimize the
number of invasive procedures to detect the highest number of cases.Four patients with higher
risk of aneuploidy during pregnancy were identified through this screening.
References
[1]
Bustillos Villavicencio, J. (2014) Protocolo: Ecografía de primer trimestre y screening de alteraciones cromosómicas y estructurales en el primer trimestre del embarazo. Servicio de Obstetricia, Hospital San Juan de Dios.
[2]
Rao, R. and Platt, L.D. (2016) Ultrasound Screening: Status of Markers and Efficacy of Screening for Structural Abnormalities. Seminars in Perinatology. WB Saunders, 67-78. https://doi.org/10.1053/j.semperi.2015.11.009
[3]
Chi, T., Huggon, I., Zosmer, N. and Nicolaides, K.H. (2001) Incidence of Major Structural Cardiac Defects Associated with Increased Nuchal Translucency But Normal Karyotype. Ultrasound in Obstetrics & Gynecology, 18, 610-614.
https://doi.org/10.1046/j.0960-7692.2001.00584.x
[4]
Agathokleous, M., Chaveeva, P., Poon, L.C.Y., Kosinski, P. and Nicolaides, K.H. (2013) Meta-Analysis of Second-Trimester Markers for Trisomy 21. Ultrasound in Obstetrics & Gynecology, 41, 247-261. https://doi.org/10.1002/uog.12364
[5]
Howard, C. (2000) Biochemical Screening for Down Syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology, 92, 97-101.
https://doi.org/10.1016/S0301-2115(00)00431-0
[6]
Ghi, T., et al. (2016) ISUOG Practice Guidelines: Invasive Procedures for Prenatal Diagnosis. Ultrasound in Obstetrics & Gynecology, 48, 256-268.
https://doi.org/10.1002/uog.15945
[7]
Nicolaides, K.H., Heath, V. and Cicero, S. (2002) Increased Nuchal Translucency at 11 - 14 Weeks. Prenatal Diagnosis, 22, 308-315. https://doi.org/10.1002/pd.308
[8]
Nicolaides, K.H., Sebire, N. and Snijders, R. (1999) Nuchal Translucency and Chromosomal Defects. In: Nicolaides, K.H., Ed., The 11 - 14 Week Scan. The Diagnosis of Fetal Abnormalities. Diploma in Fetal Medicine Series, The Parthenon Publishing Group, London, 3-65.
[9]
Cicero, S., Curcio, P., Papageorghiou, A., Sonek, J. and Nicolaides, K.H. (2001) Absence of Nasal Bone in Fetuses with Trisomy 21 at 11-14 Weeks of Gestation: An Observational Study. Lancet, 358, 1665-1667.
https://doi.org/10.1016/S0140-6736(01)06709-5
[10]
Alfirevic, Z. and Brigham, S.K. (2003) Amniocentesis and Chorionic Villus Sampling for Prenatal Diagnosis. Cochrane Database of Systematic Reviews, 3, CD003252. https://doi.org/10.1002/14651858.CD003252
[11]
Wagner, A., Mitchell, M. and Tomita-Mitchell, A. (2014) Use of Cell-Free Fetal DNA in Maternal Plasma for Noninvasive Prenatal Screening. Clinics in Perinatology, 41, 957-966. https://doi.org/10.1016/j.clp.2014.08.013
[12]
Quezada, M.S., Gil, M.M., Francisco, C., Oròsz, G. and Nicolaides, K.H. (2015) Screening for Trisomies 21, 18 and 13 by Cell-Free DNA Analysis of Maternal Blood at 10 - 11 Weeks Gestation and the Combined Test at 11 - 13 Weeks. Ultrasound in Obstetrics & Gynecology, 45, 36-41. https://doi.org/10.1002/uog.14664
[13]
Gil, M.M., Quezada, M.S., Revello, R., Akolekar, R. and Nicolaides, K.H. (2015) Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Updated Meta-Analysis. Ultrasound in Obstetrics & Gynecology, 45, 249-266.
https://doi.org/10.1002/uog.14791
